Skip to main content
Clinical Trials/NCT06406777
NCT06406777
Recruiting
Phase 1

Validation of MRI, CT and Pulmonary Function Tests for Early Detection of Chronic Lung Allograft Dysfunction

Sean Fain1 site in 1 country100 target enrollmentMarch 20, 2025

Overview

Phase
Phase 1
Intervention
Spirometry
Conditions
Chronic Lung Allograft Dysfunction Lung MRI (CLAD)
Sponsor
Sean Fain
Enrollment
100
Locations
1
Primary Endpoint
Forced expiratory volume in 1 second (FEV1) Decline
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients.

Detailed Description

This studies purpose is to confirm the efficacy and efficiency of using OE-MRI and MRI with hyperpolarized gas techniques and Iodinated contrast CT scan, this will enhance understanding of CLAD pathophysiology. Moreover, this project is foundational to performing additional studies to establish if novel MRI imaging can serve as an objective confirmatory diagnostic tool for CLAD in post-transplant patients. This observational imaging study will use 3T UTE MRI with varying oxygen levels (room air vs. 100% oxygen) to evaluate lung ventilation using oxygen enhanced imaging, in 50 healthy normal subjects (age 18-80). Subjects will have vital signs taken, complete questionnaires and have pulmonary function test (spirometry) done, Iodinated contrast CT scan and standard of care CT scans, in addition to one MRI session that will include 6 series of scans. The MRI scans will be taken in supine position (laying on back) and include breathing room air and 100% oxygen. OE-MRI will be done in addition to MRI scans with Xenon-129.

Registry
clinicaltrials.gov
Start Date
March 20, 2025
End Date
September 2028
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Sean Fain
Responsible Party
Sponsor Investigator
Principal Investigator

Sean Fain

Professor

University of Iowa

Eligibility Criteria

Inclusion Criteria

  • Ages 18-80
  • English Speaking Subjects
  • Willingness and ability to provide informed consent
  • Non-smoker
  • Lung transplant patients-inclusion criteria:
  • \>/= 6 months from lung transplant
  • History of bilateral lung transplant
  • CLAD-free patients-inclusion criteria:
  • Stable spirometry with FEV1 \> 90% of baseline value (average of 2 best values) and forced mid-expiratory flow (FEF) (25-75) \> 75% of baseline
  • Total Lung Capacity (TLC) \> 90 % of baseline

Exclusion Criteria

  • SAO2 drops below 90% (in absence of mechanical failure) during normal tidal breathing
  • Unilateral diaphragm paralysis
  • Evidence of acute illness on day of study
  • Evidence of restrictive lung disease
  • Dependence on supplemental oxygen
  • History of cardiac disease
  • Pregnancy (self-declared)
  • Lactating women
  • Participants with metal objects in their body
  • Known contraindication to MRI examination

Arms & Interventions

Healthy Normal Subjects

Healthy subjects, with no lung diagnosis, who are non-smokers.

Intervention: Spirometry

Healthy Normal Subjects

Healthy subjects, with no lung diagnosis, who are non-smokers.

Intervention: Contrast Lung Computed Tomography (CT) Scan

Healthy Normal Subjects

Healthy subjects, with no lung diagnosis, who are non-smokers.

Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Healthy Normal Subjects

Healthy subjects, with no lung diagnosis, who are non-smokers.

Intervention: 129Xe MRI scans

Post Lung Transplant with normal functioning

Subjects who have had a lung transplant and now have normal lung function

Intervention: Spirometry

Post Lung Transplant with normal functioning

Subjects who have had a lung transplant and now have normal lung function

Intervention: Contrast Lung Computed Tomography (CT) Scan

Post Lung Transplant with normal functioning

Subjects who have had a lung transplant and now have normal lung function

Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Post Lung Transplant with normal functioning

Subjects who have had a lung transplant and now have normal lung function

Intervention: 129Xe MRI scans

Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)

Subjects who have had a lung transplant that now have CLAD

Intervention: Spirometry

Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)

Subjects who have had a lung transplant that now have CLAD

Intervention: Contrast Lung Computed Tomography (CT) Scan

Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)

Subjects who have had a lung transplant that now have CLAD

Intervention: Oxygen enhanced magnetic resonance imaging (OE-MRI) Scan

Post Lung Transplant with Chronic Lung Allograft Dysfunction (CLAD)

Subjects who have had a lung transplant that now have CLAD

Intervention: 129Xe MRI scans

Outcomes

Primary Outcomes

Forced expiratory volume in 1 second (FEV1) Decline

Time Frame: Baseline and 3 months

Absolute decrease of FEV1 by 20%

Study Sites (1)

Loading locations...

Similar Trials